Merck reported strong first-quarter results, demonstrating growth across all major business units despite the upcoming patent expiry of SINGULAIR. The company's reaffirmed guidance, robust performance of key products, expansion in emerging markets, and progress in its late-stage pipeline are likely to boost investor confidence. These positive developments suggest a short-term positive impact on the stock price.

[1]